tropomyosin receptor kinase (trk) proto-oncogene protein (NTRK)
Jump to navigation
Jump to search
Pharmacology
- larotrectinib is a trk inhibitor with activity in trk fusion-positive cancers[1]
- repotrectinib (Augtyro) is FDA-aproved for all locally advanced, unresectable, or metastatic solid tumors with an NTRK gene fusion* that have progressed after initial treatment or have no alternative treatment
* NTRK gene-fusions are rare, but found in many tumor types[2]
More general terms
More specific terms
- BDNF/NT-3 growth factors receptor; EC=2.7.10.1; neurotrophic tyrosine kinase receptor type 2; TrkB tyrosine kinase; GP145-TrkB; Trk-B (NTRK2 TRKB)
- trk A protein; high affinity nerve growth factor receptor; neurotrophic tyrosine kinase receptor type 1; TRK1-transforming tyrosine kinase protein; p140-TrkA; Trk-A (NTRK1, TRK)
- trk C protein; NT-3 growth factor receptor; neurotrophic tyrosine kinase receptor type 3; TrkC tyrosine kinase; GP145-TrkC; Trk-C (NTRK3, TRKC)
- trk E proto-oncogene protein or neurotrophic tyrosine kinase, receptor-4
References
- ↑ 1.0 1.1 Drilon A, Laetsch TW, Kummar S et al Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731-739. February 22, 2018 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/29466156 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1714448
- ↑ 2.0 2.1 Alexander Otto M FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors. Medscape. June 13, 2024 https://www.medscape.com/viewarticle/fda-expands-repotrectinib-label-all-ntrk-gene-fusion-solid-2024a1000b3q